Galux and Celltrion partner on multi-온라인 바카라사이트 추천 platform to co-develop next-generation autoimmune disease treatments

[by Kang, In Hyo] Galux, an artificial intelligence (AI)-driven drug development company, announced on December 2 that it will collaborate with Celltrion, a major Korean biopharmaceutical company, to develop next-generation autoimmune disease treatments based on multiple antibodies. The companies plan to integrate Galux's AI-powered drug design platform with Celltrion's global 온라인 바카라사이트 추천 development capabilities to create differentiated multi-온라인 바카라사이트 추천 therapeutics that target multiple pathways with greater precision and efficiency.

Galux will oversee AI-based 온라인 바카라사이트 추천 design and the early validation of new drug candidates, while Celltrion will manage the entire development process, from preclinical and clinical development through commercialization. By combining their respective capabilities, the companies expect to substantially shorten the timeline from candidate discovery to clinical evaluation and to establish a novel drug development model that increases the probability of clinical success.

Multi-온라인 바카라사이트 추천 therapeutics are drawing attention as a next-generation modality because a single molecule can modulate multiple targets simultaneously, allowing for coordinated control of the complex immune pathways involved in a disease. However, conventional 온라인 바카라사이트 추천 discovery methods depend on random screening, making it difficult to obtain a sufficiently diverse repertoire of antibodies capable of binding to each target. In addition, experimentally combining these antibodies to generate optimal multi-온라인 바카라사이트 추천 structures remains limited, presenting a fundamental constraint.

Galux's AI-based protein design technology precisely models the molecular-level interactions between therapeutic targets and antibodies, enabling the incorporation of key structural features required for optimal therapeutic development from the outset. This technology differentiates itself by allowing the rapid identification of novel drug candidates with superior properties, even in the context of complex multi-온라인 바카라사이트 추천 development.

Recently, Galux demonstrated industry-leading capabilities in both design precision and success rate, reporting a de novo antibody design success rate exceeding 30% for multiple targets using its ‘GaluxDesign’ platform. According to the company, this high-precision design performance is drawing considerable attention from the global biopharmaceutical industry.

Celltrion, a leading pharmaceutical and biotechnology company with proven global competitiveness in antibody biopharmaceuticals and biosimilars, has recently strengthened its ‘open innovation’ strategy by actively incorporating external cutting-edge technologies to develop novel drugs across various modalities, including multi-antibody therapeutics and antibody-drug conjugates (ADCs). This collaboration, combining Celltrion's extensive development and clinical expertise with Galux's innovative AI-driven design platform, is expected to dramatically accelerate the pace and enhance the success rate of next-generation antibody therapeutics.

"AI-based protein design technology does more than simply reduce costs and shorten development timelines, it represents a paradigm shift in novel drug development. By leveraging AI to precisely engineer new drug candidates with predefined structures and functions from the outset, the platform enables truly optimal therapeutic design. This collaboration is particularly meaningful, as it allows us to apply the next-generation development model in real-world industrial settings together with Celltrion," said Seok Cha-ok, CEO of Galux.

“To develop challenging novel therapeutics such as multi-antibody drugs, it is essential to adopt new and diverse approaches that overcome existing technological limitations. Through our collaboration with Galux, we aim to lead the evolving paradigm of drug development and establish a foundation for the sustainable growth of the Korean biotechnology ecosystem,” stated Lee Soo-young, Head of Celltrion’s New Drug Research Division.